1 June 2023 in Drug Design, Development and Therapy
Metformin has been designated as one of the most crucial first-line therapeutic agents in the management of type 2 diabetes mellitus. Primarily being an antihyperglycemic agent, metformin also has a plethora of pleiotropic effects on various systems and processes. It acts majorly by activating AMPK (Adenosine Monophosphate-Activated Protein Kinase) in the cells and reducing glucose output from the liver. It also decreases advanced glycation end products and reactive oxygen species production in the endothelium apart from regulating the glucose and lipid metabolism in the cardiomyocytes, hence minimizing the cardiovascular risks. Its anticancer, antiproliferative and apoptosis-inducing effects on malignant cells might prove instrumental in the malignancy of organs like the breast, kidney, brain, ovary, lung, and endometrium. Preclinical studies have also shown some evidence of metformin’s neuroprotective role in Parkinson’s disease, Alzheimer’s disease, multiple sclerosis and Huntington’s disease. Metformin exerts its pleiotropic effects through varied pathways of intracellular signalling and exact mechanism in the majority of them remains yet to be clearly defined. This article has extensively reviewed the therapeutic benefits of metformin and the details of its mechanism for a molecule of boon in various conditions like diabetes, prediabetes, obesity, polycystic ovarian disease, metabolic derangement in HIV, various cancers and aging.
11 July 2026 in European Journal of Obstetrics & Gynecology and Reproductive Biology
PSPinky Saras Kumar Sahoo
1 January 2025 in Journal of Dental Anesthesia and Pain Medicine
Bansal S, et al. J Dent Anesth Pain Med. 2025 Oct;25(5):299-312. https://doi.org/10.17245/jdapm.2025.25.5.299
27 August 2026 in Journal of Infection Prevention
Background: Healthcare workers in critical care settings are at increased risk of acquiring respiratory infections, particularly during aerosol-generating procedures (AGPs). Portable negative-pressure isolation devices have been proposed to fix airborne infection in isolation rooms. Objective: To evaluate whether an isolated negative-pressure device reduces bacterial and fungal aerosol dispersion under controlled laboratory conditions. Methods: This laboratory-based controlled experimental observational study assessed aerosol containment across three techniques: (1) no cover, (2) plastic sheet canopy barrier, and (3) a portable negative-pressure isolation system. Standardized 5 mL suspensions of Staphylococcus epidermidis and Aspergillus flavus were nebulized on three separate days for each technique. Nutrient agar plates were placed and colony-forming units (CFU) were manually counted. The primary outcome was the mean CFU per technique per day. One-way ANOVA with post-hoc Welch’s t -tests (Bonferroni-corrected) was used for statistical comparison. Results: A total of 36 bacterial and fungal plates were analysed. For bacterial aerosols, mean CFU was highest with no cover (535.6 ± 5.38), lower with plastic sheet canopy barrier (429.5 ± 5.41), and lowest with the negative-pressure system (217.5 ± 17.5). Differences were statistically significant (ANOVA p = 9.8 × 10 −8 ; η 2 = 0.995). Fungal CFU demonstrated a similar pattern with significantly lower CFU for Technique 3 compared with both other techniques ( p < .001). Conclusion: The negative-pressure isolation device significantly reduced airborne dispersion of bacterial and fungal aerosols compared with plastic sheet canopy barrier methods. These findings support the use of portable negative-pressure systems to enhance aerosol containment during AGPs. Further clinical validation is recommended.